Nektar Therapeutics (NKTR) Total Liabilities (2010 - 2026)

Nektar Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $187.1 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 22.86% year-over-year to $187.1 million in Q1 2026; TTM through Mar 2026 was $187.1 million, a 22.86% decrease from a year earlier, with the FY2025 full-year figure at $190.6 million, down 21.61% from the prior year.
• Total Liabilities fell to $187.1 million in Q1 2026 per NKTR's latest filing, from $190.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $416.2 million in Q1 2022 and bottomed at $187.1 million in Q1 2026.
• The 5-year median for Total Liabilities is $267.0 million (2023), against an average of $282.6 million.
• Across the five-year window, Total Liabilities slipped 26.27% in 2023 and slipped 8.41% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $344.0 million in 2022, then retreated by 22.36% to $267.0 million in 2023, then declined by 8.96% to $243.1 million in 2024, then decreased by 21.61% to $190.6 million in 2025, then decreased by 1.85% to $187.1 million in 2026.
• Per Business Quant, the three latest NKTR Total Liabilities figures stand at $187.1 million (Q1 2026), $190.6 million (Q4 2025), and $216.3 million (Q3 2025).